May 17

At the University of NEW YORK Lineberger Comprehensive Cancer Center.

Related StoriesFDA grants accelerated acceptance for Tagrisso to take care of patients with advanced NSCLCMeat-rich diet plan may increase kidney cancer riskOvarian cancer sufferers with a brief history of oral contraceptive make use of have got better outcomesThis trial may be the subject of a particular protocol evaluation with the FDA, which means that the design, clinical endpoints and statistical analyses of the trial have already been previously agreed upon by the FDA.This compares to a net loss relevant to common stockholders of $1.5 million for the first quarter of 2013, which included accretion on desired stock of $0.9 million, or per share. The first quarter 2013 net reduction and net loss relevant to common stockholders also included a $2.4 million gain on the extinguishment of debt linked to the 2012 Series X recommended stock. In connection with the closing of the Firm's initial open public offering on March 25, 2014, all of the ongoing company;s outstanding shares of preferred share were converted into shares of common stock.2 million for the first quarter of 2014 compared to $1.9 million for the 1st quarter of 2013.